Your session is about to expire
← Back to Search
Using Ex-vivo Normothermic Machine Perfusion With the Organox Metra™ Device to Store Human Livers for Transplantation
Phase 1
Waitlist Available
Led By David R Grant, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will test if using the OrganOx Metra device to keep donor livers warm and nourished before transplantation is safe and practical. It aims to help patients needing liver transplants by ensuring the livers are in good condition, which could make more livers available and improve transplant success. The OrganOx Metra device has been shown to be cost-effective and improve patient outcomes by reducing early liver problems and adverse events.
Eligible Conditions
- End Stage Liver Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Ischemia- reperfusion injury associated with organ storage
Recruitment rates to the study
The ability of perfusion parameters to predict clinical outcomes following transplantation
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: OrganOx MetraExperimental Treatment1 Intervention
OrganOx Metra Device
Find a Location
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,527 Previous Clinical Trials
503,506 Total Patients Enrolled
David R Grant, MDPrincipal InvestigatorUniversity Health Network, Toronto